TREATMENT RHEUMATOID ARTHRITIS WITH ADALIMUMAB IN THE SOUTHERN REGION OF KYRGYZSTAN: A 24 MONTH FOLLOW UP
DOI:
https://doi.org/10.52754/16948610_2024_4_6Keywords:
rheumatoid arthritis, biological DMARDs, adalimumab, tumor necrosis factor-α, RA, DAS28, Health Assessment Questionnaire-Disability IndexAbstract
Rheumatoid arthritis (RA) is a persistent autoimmune condition marked by inflammation, particularly in the small joints, along with pain, elevated acute inflammatory markers (CRP and ESR), and increased levels of specific proteins (RF and ACPA). This study aims to offer detailed insights into the safety and effectiveness of adalimumab in managing rheumatoid arthritis in the southern region of Kyrgyzstan. A prospective observational study was carried out from 2021 to 2023, involving 36 patients who had a confirmed RA diagnosis (with disease duration of less than 24 months) according to the criteria set by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR). These patients had not responded to conventional disease-modifying anti-rheumatic drugs. The findings from this study indicate that a 24-month course of adalimumab treatment leads to a significant decrease in disease activity, as measured by DAS28.
References
Авдеева А. С., Аланцева Ж. В., Александрова Е. Н., Мазуров В. И. Генно-инженерные биологические препараты в лечении ревматоидного артрита // ИМА-Пресс. Москва, 2013. – 552 с. ISBN 978-5-904356-20-0. EDN TKRBIJ.
Каратеев Д. Е., Насонов Е. Л., Лучихина Е. Л. Эффективность и безопасность лечения адалимумабом больных активным ревматоидным артритом с резистентностью к стандартной терапии: результаты Российского национального исследования // Тер арх. 2012. – No 8. – Т. 84. – С. 22–28.
Мазуров В. И., Беляева И. Б. Клиническая значимость ингибиторов Янус-киназ в терапии ревматоидного артрита: достижения и перспективы // Современная ревматология. 2019. – No 4. – Т. 13. – С. 116–123.
Мамасаидов А. Т., Салиева Р. Ш. Анти-В-клеточная терапия при ревматоидном артрите с бронхиолитом // Вестник медицины и образования. 2023. – No 3. – С. 37–43. ISSN: 1694-8459.
Bombardier C., Gladman D. D., Urowitz M. B. Safety of adalimumab in rheumatoid arthritis // J Rheumatol. 2012 Dec. – Т. 39(12). – С. 2330–2336.
Burmester G. R., Mease P., Dijkmans B. A. Adverse events in patients treated with adalimumab // Ann Rheum Dis. 2011 Jun. – Т. 70(6). – С. 1044–1049.
Codreanu C., Damjanov N. Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries // Biologics. 2015 Jan 27. – Т. 9. – С. 1–6. https://doi.org/10.2147/BTT.S68949. DOI: https://doi.org/10.2147/BTT.S68949
Curtis J. R., Patkar N., Xie A. Serious infections in patients with rheumatoid arthritis: a prospective study // Ann Intern Med. 2007 Feb 6. – Т. 146(4). – С. 258–265.
Fautrel B., Kirkham B., Pope J. E. Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM // J Clin Med. 2019 Sep 5. – Т. 8(9). – С. 1394. https://doi.org/10.3390/jcm8091394. DOI: https://doi.org/10.3390/jcm8091394
Finzel S., Kraus S., Figueiredo C. P. Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis // Ann Rheum Dis. 2019 Sep. – Т. 78(9). – С. 1186–1191. https://doi.org/10.1136/annrheumdis-2018-214894. DOI: https://doi.org/10.1136/annrheumdis-2018-214894
Hetland M. L., Christensen I. J., Tarp U. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry // Arthritis Rheum. 2010 Jan. – Т. 62(1). – С. 22–32. https://doi.org/10.1002/art.27227. DOI: https://doi.org/10.1002/art.27227
Kay J., Jaworski J., Wojciechowski R. Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study // Arthritis Res Ther. 2021 Feb 5. – Т. 23(1). – С. 51. https://doi.org/10.1186/s13075-020-02394-7. DOI: https://doi.org/10.1186/s13075-020-02394-7
Keystone E. C., Genovese M. C., Klareskog L. Long-term safety and efficacy of adalimumab in patients with rheumatoid arthritis: results from a randomized controlled trial // Arthritis Rheum. 2004 Mar. – Т. 50(4). – С. 1047–1059. https://doi.org/10.1002/art.20233. DOI: https://doi.org/10.1002/art.20233
Lu X., Hu R., Peng L. Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis // Front Immunol. 2021 Apr 6. – Т. 12. – С. 638444. https://doi.org/10.3389/fimmu.2021.638444. DOI: https://doi.org/10.3389/fimmu.2021.638444
Matcham F., Rayner L., Steer S. Psychological distress in patients with rheumatoid arthritis: a systematic review and meta-analysis // Rheumatology (Oxford). 2016 Dec. – Т. 55(12). – С. 2134–2142. https://doi.org/10.1093/rheumatology/kew203. DOI: https://doi.org/10.1093/rheumatology/kew203
Schiff M., Pritchard C., Huffstutter J. E. Infections in patients receiving TNF inhibitors: a review // Clin Infect Dis. 2008 Sep 1. – Т. 47(3). – С. 307–310. https://doi.org/10.1086/589240. DOI: https://doi.org/10.1086/589240
Smolen J. S., Aletaha D., McInnes I. B. Rheumatoid arthritis // Lancet. 2016 Oct 22. – Т. 388(10055). – С. 2023–2038. https://doi.org/10.1016/S0140-6736(16)30173-8. DOI: https://doi.org/10.1016/S0140-6736(16)30173-8
Smolen J. S., van der Heijde D., St Clair E. W. Efficacy of adalimumab in patients with rheumatoid arthritis // Ann Rheum Dis. 2007 Apr. – Т. 66(4). – С. 465–471. https://doi.org/10.1136/ard.2006.063040.
Strand V., Tundia N., Bergman M. Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE // Rheumatology (Oxford). 2021 Dec 1. – Т. 60(12). – С. 5583–5594. https://doi.org/10.1093/rheumatology/keab158. DOI: https://doi.org/10.1093/rheumatology/keab158
Taylor P. C., Lee Y. C., Fleischmann R. Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial // J Clin Med. 2019 Jun 12. – Т. 8(6). – С. 831. https://doi.org/10.3390/jcm8060831. DOI: https://doi.org/10.3390/jcm8060831
van de Putte L. B., Atkins C. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed // Ann Rheum Dis. 2004 May. – Т. 63(5). – С. 508–516. https://doi.org/10.1136/ard.2003.013052. DOI: https://doi.org/10.1136/ard.2003.013052
Weinblatt M. E. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis // Arthritis Rheumatol. 2018 Jan. – Т. 70(1). – С. 40–48. https://doi.org/10.1002/art.40336. DOI: https://doi.org/10.1002/art.40336
Weinblatt M. E., Keystone E. C., Furst D. E. Efficacy of adalimumab in patients with rheumatoid arthritis // Arthritis Rheum. 2003 Jan. – Т. 48(1). – С. 35–45. https://doi.org/10.1002/art.10752. DOI: https://doi.org/10.1002/art.10752
Mihara M., Ohsugi Y., Kishimoto T. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis // Open Access Rheumatol. 2011 Feb 25. – Т. 3. – С. 19–29. https://doi.org/10.2147/OARRR.S17118. DOI: https://doi.org/10.2147/OARRR.S17118
Ogata A., Kato Y., Higa S., Yoshizaki K. IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review // Modern Rheumatology. 2019 Mar 4. – Т. 29(2). – С. 258–267. https://doi.org/10.1080/14397595.2018.1546357. DOI: https://doi.org/10.1080/14397595.2018.1546357
Edwards J. C. W., Szczepański L., Szechiński J., Filipowicz-Sosnowska A., Emery P., Close D. R., Stevens R. M., Shaw T. Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis // N Engl J Med. 2004 Jun 17. – Т. 350(25). – С. 2572–2581. https://doi.org/10.1056/NEJMoa032534. DOI: https://doi.org/10.1056/NEJMoa032534
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
